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Aim: To evaluate the long-term safety and efficacy of canagliflozin as add-on therapy in
patients with type 2 diabetes mellitus (T2DM) who had inadequate glycaemic control with
teneligliptin monotherapy.
Methods: This open-label 52-week study was conducted in Japan. Patients received canagliflo-
zin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks. The safety endpoint
was the incidence of adverse events (AEs). The efficacy endpoints included changes in glycated
haemoglobin (HbA1c), fasting plasma glucose (FPG) and body weight from baseline to week
52 (with last observation carried forward).
Results: Overall, 153 patients entered the treatment period and 142 completed the study.
The overall incidence rates of AEs and drug-related AEs were 69.9% and 22.9%, respectively.
Most AEs and drug-related AEs were mild or moderate in severity. There were no previously
undescribed safety signals. The mean changes in HbA1c, FPG and body weight were −0.99%
(95% confidence interval [CI] −1.12 to −0.85), −38.6 mg/dL (95% CI −43.4 to −33.9) and
−3.92% (95% CI −4.53 to −3.31), respectively. These effects were maintained for 52 weeks
without attenuation. HbA1c and body weight were both decreased in 82.24% of patients at
the end of the treatment period. Reductions in postprandial glucose were observed at weeks
24 and 52.
Conclusions: No new safety risks with this combination were identified, and sustained improve-
ments in HbA1c, FPG and body weight were observed. The findings suggest that long-term co-
administration of canagliflozin with teneligliptin is well tolerated and effective in Japanese
patients with T2DM who have inadequate glycaemic control on teneligliptin alone.
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1 | INTRODUCTION
Over the past decade, several classes of oral glucose-lowering agents
have been launched, including dipeptidyl peptidase-4 (DPP-4)
inhibitors and sodium-glucose co-transporter-2 (SGLT2) inhibitors.1
DPP-4 inhibitors increase levels of the active forms of glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide
after food intake, which in turn promote insulin secretion
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and suppress glucagon secretion. Because these mechanisms are
glucose-dependent, the risk of hypoglycaemia is low.1,2 SGLT2 inhibi-
tors suppress glucose reabsorption in the renal tubules and exert
antihyperglycaemic effects in an insulin-independent manner. This
class of drug reduces both blood glucose levels and body weight1,3;
however, it has been reported that SGLT2 inhibitors cause a rise in
glucagon levels and enhance gluconeogenesis.3–5 Owing to these dif-
ferences in their mechanisms of action, the combined use of both
types of inhibitor has been reported to be beneficial because they act
in a complementary manner,6,7 and 2 fixed-dose combination pro-
ducts have been launched in Western countries.7
Diabetes mellitus is caused by impaired insulin secretion and
insulin resistance8; however, there are differences in the pathology of
type 2 diabetes mellitus (T2DM) between Japanese and Caucasian
subjects. The dominant pathology in Japanese individuals is impaired
insulin secretion, while that in Caucasian individuals is insulin resist-
ance.2,9 Although metformin is the first-line drug in Western
countries,10 the use of DPP-4 inhibitors has been increasing in Japan:
according to an analysis of the Japan Medical Data Centre Claims
Database (Japan Medical Data Centre Co. Ltd, Tokyo, Japan), ~70%
of Japanese patients with T2DM use DPP-4 inhibitors, and ~60% of
patients receiving DPP-4 inhibitors are drug-naïve.2 In some cases,
however, it is difficult to control blood glucose using a DPP-4 inhibi-
tor alone.11–13 In such cases, combining a DPP-4 inhibitor with an
SGLT2 inhibitor is a possible option, but this combination has yet to
be fully evaluated in Japanese patients. Owing to the differences in
T2DM pathology and treatment algorithms between Japanese and
Western populations, the results of studies examining combination
therapy with a DPP-4 inhibitor and an SGLT2 inhibitor in Western
patients may not be generalizable to Japanese patients; therefore, it
is important to examine the efficacy and safety of this combination in
Japanese patients.
The DPP-4 inhibitor teneligliptin has been approved in Japan and
Korea for the treatment of T2DM.14,15 The 1-year efficacy and safety
of teneligliptin as monotherapy and in combination with oral antidia-
betic drugs (other than SGLT2 inhibitors) in Japanese patients with
T2DM have been evaluated.16,17 In addition, its combination with
metformin was evaluated in a European multicentre study.18 Canagli-
flozin is an SGLT2 inhibitor approved for the treatment of T2DM in
North America, Latin America, Europe and the Asia-Pacific region,
including Japan.19 A recently completed 24-week, double-blind study
demonstrated the safety and efficacy, including during a mixed-meal
tolerance test, of canagliflozin add-on therapy to teneligliptin in Japa-
nese patients with T2DM who had inadequate glycaemic control on
teneligliptin monotherapy.20 In the present study, we report the
safety and efficacy of teneligliptin and canagliflozin combination ther-
apy, including the results of mixed-meal tolerance tests and subgroup
analyses according to patient characteristics, over the longer term
(52 weeks) in patients with inadequate glycaemic control on teneli-
gliptin alone. In addition, because of the increasing recognition of the
importance of composite endpoints in T2DM trials,21 the percentage
of patients with decreases in both glycated haemoglobin (HbA1c) and
body weight at the end of treatment was evaluated in a post hoc
analysis.
2 | MATERIALS AND METHODS
2.1 | Study design
This 52-week, open-label study was performed in 24 institutions in
Japan. The participating institutions/investigators are listed in Appen-
dix S1.
2.2 | Patients
The study included Japanese patients with T2DM with inadequate
glycaemic control on teneligliptin and diet and exercise therapy. The
inclusion criteria were as follows: age ≥20 years; glycated haemoglo-
bin (HbA1c) ≥7.0% and <10.5%; fasting plasma glucose (FPG) concen-
tration ≤270 mg/dL; and diet and exercise therapy for diabetes for
>12 weeks before the treatment period. Patients meeting the follow-
ing criteria at the screening visit were excluded from the study: type
1 diabetes; diabetes mellitus resulting from a pancreatic disorder, or
secondary diabetes; serious complications of diabetes; hereditary
glucose-galactose malabsorption or primary renal glucosuria; class
III/IV heart failure symptoms according to the New York Heart Asso-
ciation functional classification; and severe hepatic or severe renal
disorder.
2.3 | Interventions
Patients underwent a washout period of >12 weeks in which they
stopped all antidiabetic drugs, except for teneligliptin, before the
treatment period. Patients continued their fixed programme of diet
and exercise therapy during the washout period. Teneligliptin and
canagliflozin were orally administered at doses of 20 and 100 mg,
respectively (the approved doses in Japan), once daily before break-
fast for 52 weeks. Diet and exercise therapy continued unchanged
during the treatment period. A 2-week observation period followed
the treatment period. Mixed-meal tolerance tests were performed at
baseline, week 24 and week 52 using a method similar to that
reported in a previous study.20 Visits were scheduled every 4 weeks
during the treatment period, and at 2 weeks after study completion
or at study withdrawal (if before week 52).
2.4 | Outcomes
The safety evaluation included assessments of adverse events (AEs),
hypoglycaemia, laboratory values, ECG, and vital signs. AEs and
safety assessments were recorded throughout the study by the study
investigators, and were not limited to the time of hospital visits. AEs
were listed using Medical Dictionary for Regulatory Activities
(Version 18.1) system organ class and preferred terms, and their
potential relationships to the study drug (no causal relationship or a
possible causal relationship, ie, adverse drug reactions; ADRs) and
severity (mild, moderate or severe) were assessed.
The efficacy evaluation included the following assessments:
change from baseline in HbA1c, FPG, body weight, proinsulin/C-
peptide ratio and homeostatis model assessment 2 steady state beta-
cell function (HOMA2-%B) values; and evaluation of postprandial glu-
cose, glucagon and C-peptide at weeks 24 and 52 in the mixed-meal
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tolerance test. HbA1c was measured by high-performance liquid
chromatography using a reference standard approved by the US
National Glycohemoglobin Standardization Program. Glucagon was
measured by radioimmunoassay (SCETI K.K., Tokyo, Japan). All effi-
cacy and safety laboratory measurements were assayed at a central
laboratory (LSI Medience Corporation, Tokyo, Japan). Prespecified
subgroup analyses were performed to evaluate the safety and effi-
cacy of this combination therapy in patients subdivided on the basis
of the following background factors: HbA1c <8% and ≥8%; body
mass index (BMI) <25 and ≥25 kg/m2; and estimated glomerular fil-
tration rate (eGFR) <60 mL/min/1.73 m2, ≥60 to <90 mL/min/
1.73 m2 and ≥90 mL/min/1.73 m2.
2.5 | Statistical methods
Safety analyses were performed in the safety analysis set, which
comprised all patients, excluding those who did not receive a dose of
the study drug or who lacked safety data after starting administration
of the study drug. Efficacy analyses were performed in the full analy-
sis set, which comprised all patients, excluding those who did not
receive a dose of the study drug or who had no efficacy data after
starting administration of the study drug. Descriptive statistics of
values measured at each time point and at the end of the treatment
period were calculated for each variable. Changes in efficacy variables
from baseline to week 52 were determined using the last observation
carried forward (LOCF) to impute missing values. Descriptive statis-
tics and 95% confidence intervals (CIs) were calculated for changes
or percent changes from baseline to each measurement time point
and the end of the treatment period. HbA1c <7.0% and <8.0% suc-
cess rates and 95% CI (based on the F distribution) at the end of the
treatment period were calculated. Using individual patient data, the
correlation between changes in HbA1c and body weight from base-
line and a composite endpoint (the percentage of patients with
decreases in both HbA1c and body weight) at the end of the treat-
ment period were evaluated in post hoc analyses. Owing to the
descriptive nature of the analyses, P values were not calculated. All
statistical analyses were performed using Windows SAS version 9.2
or later.
2.6 | Ethical considerations
The trial was registered at clinicaltrials.gov (identifier NCT02220907),
and was carried out in accordance with the ethical principles of the
Declaration of Helsinki, the Law for Ensuring the Quality, Efficacy,
and Safety of Drugs and Medical Devices, Good Clinical Practice
guidelines, and the approved study protocol practice. The study was
approved by the ethics committee/institutional review boards at all




Of the 200 patients who consented to participate, 153 entered the
treatment period and 142 completed the study. All 153 patients were
included in the full analysis set and safety analysis set. Patient charac-
teristics are described in Table 1. Of the 153 patients, 108 (70.6%)
were men. The mean  standard deviation (s.d.) age and BMI were
56.1  10.4 years and 26.52  4.47 kg/m2, respectively. The mean
 s.d. baseline HbA1c and FPG were 8.14%  0.94% and
177.3  34.8 mg/dL, respectively.
3.2 | Safety
A summary of the AEs is shown in Table 2. The overall incidence of
AEs and ADRs at 52 weeks was 69.9% (107/153 patients;
269 events) and 22.9% (35/153 patients; 45 events), respectively.
There were 13 serious AEs in 11 patients, including one ADR in one
patient. The serious AEs observed were cataract, myocardial infarc-
tion, ankle fracture, influenza, pneumonia, disseminated herpes zos-
ter, rectal cancer, hepatocellular carcinoma, atrial fibrillation and sinus
node dysfunction. A serious ADR of myocardial infarction occurred in
1 patient.
A total of 9 AEs, including 4 ADRs, led to discontinuation in
7 and 3 patients, respectively. AEs that led to discontinuation were
myocardial infarction, vulvar vaginal candidiasis, rectal cancer, hepa-
tocellular carcinoma, atrial fibrillation, sinus node dysfunction, eczema
and balanoposthitis. ADRs that led to discontinuation were vulvar
vaginal candidiasis, myocardial infarction, eczema and balanoposthitis.
No AEs resulted in death during the study.
Table 2 shows the AEs of special interest. No other AEs of spe-
cial interest were observed. For canagliflozin, the AEs included ketoa-
cidosis and sepsis. For teneligliptin, the AEs were intestinal
obstruction and interstitial pneumonia. Laboratory values are pre-
sented in Table S1, Appendix S1.
TABLE 1 Demographics and baseline characteristics (safety analysis





Age(years), mean(s.d) 56.1 (10.4)
Duration of diabetes(years), mean(s.d.) 9.07 (5.55)
Body weight (kg), mean(s.d.) 72.12 (14.87)
BMI (kg/m2), mean(s.d.) 26.52 (4.47)
Diabetic complications, n (%)
Total 68 (44.4)
Diabetic retinopathy 24 (15.7)
Diabetic neuropathy 16 (10.5)
Diabetic nephropathy 51 (33.3)
Non-diabetic complications, n (%)
Hypertension 89 (58.2)
Hyperlipidaemia 128 (83.7)
HbA1c (%), mean(s.d.) 8.14 (0.94)
Fasting plasma glucose(mg/dL), mean(s.d.) 177.3 (34.8)
eGFR(mL/min/1.73m2), mean(s.d.) 86.7 (19.2)
a Fasting plasma glucose: 1 mg/dL = 0.0555 mmol/L.
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3.3 | Efficacy
A decrease in HbA1c from baseline to week 52 (LOCF) was observed,
with a mean change of −0.99% (95% CI −1.12 to −0.85; Table 3). The
decrease in HbA1c was apparent at week 4; HbA1c then continued
to decrease to week 12, gradually decreased thereafter, and its level
was maintained until week 52 (Figure 1A). The proportions of
patients who achieved HbA1c <7% and HbA1c <8% at week 52 were
43.75% (95% CI 35.51–52.26) and 72.37% (95% CI 60.91–82.01),
respectively. A decrease in FPG was detected by week 4 and was
maintained until week 52 (Figure 1B). The mean change in FPG from
baseline to week 52 (LOCF) was −38.6 mg/dL (95% CI −43.4 to
−33.9; Table 3). A decrease in body weight was detected by week
4. Body weight continued to decrease until week 20 and was main-
tained until week 52 (Figure 1C). The change and percent change in
body weight from baseline to week 52 (LOCF) were −2.86 kg (95%
CI −3.42 to −2.31) and −3.92% (95% CI −4.53 to −3.31), respectively
(Table 3). Figure 1D is a scatter plot of the change in HbA1c vs the
percent change in body weight from baseline to week 52 (LOCF). As
indicated in this figure, decreases in both HbA1c and body weight
occurred in 82.24% of patients. The change in HbA1c was not corre-
lated with the percent change in body weight (r = 0.2778).
Regarding other efficacy endpoints, the mean changes in the fast-
ing proinsulin/C-peptide ratio and HOMA2-%B values from baseline
to week 52 (LOCF), as markers of β-cell function, were −0.0047 (95%
CI −0.0059 to −0.0036) and 10.91% (95% CI 8.79-13.03), respectively
(Table 3). Other efficacy endpoints, including the changes from base-
line to week 52 (LOCF) for systolic and diastolic blood pressure, trigly-
cerides and HDL cholesterol, are summarized in Table S2, Appendix
S1. Systolic and diastolic blood pressure was decreased and HDL cho-
lesterol increased during this time. Figure 2 shows the results of the
mixed-meal tolerance test, with actual values of glucose, C-peptide
and glucagon after the meal at baseline, week 24 and week 52. As
shown in Figure 2A, plasma glucose values measured at 0, 0.5, 1 and
2 hours were substantially lower at weeks 24 and 52 than at baseline.
The changes in 2-hour postprandial glucose from baseline to weeks
24 and 52 were −63.3 mg/dL (95% CI −71.5 to −55.0) and −60.7 mg/
dL (95% CI −69.9 to −51.5), respectively (Table S3, Appendix S1). The
time courses of plasma C-peptide and glucagon were similar after
treatment compared with baseline except that glucagon at each time
point was lower at week 24 (Figure 2B,C). The mixed-meal tolerance
test also showed decreases from baseline in area under the curve
(AUC)0-2h at weeks 24 and 52 in postprandial plasma glucose
(Table S3, Appendix S1). Although the postprandial C-peptide AUC0-2h
did not increase after treatment, the C-peptide AUC0-2h/blood glucose
AUC0-2h ratio showed an increase from baseline at weeks 24 and 52.
The postprandial glucagon AUC0-2h was decreased at week 24, and
the difference became smaller at week 52. The incremental 2-hour
postprandial plasma glucose and incremental postprandial plasma glu-
cose AUC0-2h decreased, while the incremental C-peptide AUC0-2h/
blood glucose AUC0-2h ratio increased at weeks 24 and 52 compared
with baseline (Table S3, Appendix S1).
TABLE 2 Adverse events occurring during the study (safety analysis
set, N = 153)
AEs n (%)
AEs 107 (69.9)
Drug-related AEs 35 (22.9)
Serious AEs 11 (7.2)
Serious drug-related AEs 1 (0.7)
AEs leading to discontinuation 7 (4.6)
Drug-related AEs leading to discontinuation 3 (2.0)
AEs of special interest
Documented hypoglycaemia 4 (2.6)
Osmotic diuresis 15 (9.8)
Volume depletion 2 (1.3)
Genital infection (males) 1/108 (0.9)
Genital infection (females) 5/45 (11.1)
Urinary tract infection 2 (1.3)
Fracture 3 (2.0)
Blood ketone body increased 3 (2.0)
Hepatic function impairment 2 (1.3)
Skin and subcutaneous tissue disorders 13 (8.5)
Cardiovascular-related events 3 (2.0)
Malignant neoplasm 2 (1.3)
Gastrointestinal disorders 23 (15.0)
TABLE 3 Effects of canagliflozin and teneligliptin combination
therapy on efficacy endpoints (full analysis set, N = 153)
Variable Value
HbA1c, % (n = 153)
Baseline, mean (s.d.) 8.14 (0.94)
Change from baseline (LOCF), mean (s.d.) −0.99 (0.84)
95% CI −1.12 to −0.85
FPG, mg/dL (n = 152)
Baseline, mean (s.d.) 177.1 (34.8)a
Change from baseline (LOCF), mean (s.d.) −38.6 (1.66)
95% CI −2.14 to −1.88
Body weight, kg (n = 152)
Baseline, mean (s.d.) 72.08 (14.91)a
Change from baseline (LOCF), mean (s.d.) −2.86 (3.46)
95% CI −3.42 to −2.31
Percent change from baseline (LOCF), mean
(s.d.)
−3.92 (3.81)
95% CI −4.53 to −3.31
Fasting proinsulin/C-peptide ratio (n = 152)
Baseline, mean (s.d.) 0.0197 (0.0114)a
Change from baseline (LOCF), mean (s.d.) −0.0047 (0.0073)
95% CI −0.0059 to
−0.0036
HOMA2-%B, % (n = 152)
Baseline, mean (s.d.) 35.00 (16.53)a
Change from baseline (LOCF), mean (s.d.) 10.91 (13.23)
95% CI 8.79 to 13.03
Fasting glucagon, pg/mL (n = 152)
Baseline, mean (s.d.) 125.3 (21.8)a
Change from baseline (LOCF), mean (s.d.) −0.6 (22.1)
95% CI −4.1 to 2.9
a Baseline mean (s.d.) values for the population with LOCF data.
b FPG: 1 mg/dL = 0.0555 mmol/L. Glucagon: 1 pg/mL = 1 ng/L.
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3.4 | Subgroup analyses of safety and efficacy
according to background characteristics
The results of the prespecified subgroup analysis according to baseline
HbA1c, BMI and eGFR are shown in Tables S4 and S5, Appendix S1.
Because a small number of patients with eGFR <60 mL/min/1.73 m2
were enrolled, no further analysis was possible in this group.
The extent of the decrease in HbA1c was greater in subgroups
with higher baseline HbA1c (≥8%) and higher baseline eGFR
FIGURE 1 Changes in A, HbA1c; B, FPG and C, body weight from baseline during the study period. Data represent mean (95% CI). D, Scatter plot of
the change in HbA1c vs percent change in body weight from baseline to the end of treatment in individual patients. FPG: 1 mg/dL = 0.0555 mmol/L.
FIGURE 2 Changes in A, blood glucose; B, C-peptide and C, glucagon levels in the mixed-meal tolerance tests at baseline, week 24 and week 52.
Data represent mean  standard deviation. Glucose: 1 mg/dL = 0.0555 mmol/L; C-peptide: 1 ng/mL = 0.333 nmol/L; Glucagon: 1 pg/mL = 1 ng/L.
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(≥90 mL/min/1.73 m2), but the change in HbA1c did not differ
among the BMI subgroups. The body weight change (%) did not differ
among the subgroups (Table S4, Appendix S1). Baseline HbA1c, BMI
and eGFR had no effect on the overall incidence of AEs or ADRs
(Table S5, Appendix S1).
4 | DISCUSSION
This study examined the long-term safety and efficacy of canagliflo-
zin added on to teneligliptin in Japanese patients with T2DM. In par-
ticular, we observed no new safety concerns after administering this
combination of drugs compared with previous studies of canagliflozin
and teneligliptin.16,17,22 We also observed reductions in HbA1c, FPG
and body weight during the study. These effects were apparent
within ~4 weeks of starting treatment, and were maintained for
52 weeks without attenuation. The reduction in postprandial glucose
levels was also maintained for 52 weeks.
A recent 24-week randomized, placebo-controlled trial examined
the safety and efficacy of canagliflozin added on to teneligliptin in
Japanese patients with T2DM, and showed that this combination was
well tolerated and effective.20 In that study, the addition of canagli-
flozin was associated with significant improvements in HbA1c, FPG,
body weight and postprandial plasma glucose-related variables. The
present study not only confirms the results of this previous study,
but also shows that the improvements in HbA1c, FPG, body weight
and postprandial glucose were maintained over a longer time period
(52 weeks vs 24 weeks). Similarly to the present study, Inagaki
et al.22 also conducted an open-label, long-term (52-week) study of
the safety and efficacy of canagliflozin (100 or 200 mg) as monother-
apy or added on to other oral antihyperglycaemic drugs, including
DPP-4 inhibitors (sitagliptin, vildagliptin or alogliptin) in Japan. Other
52-week studies in Japanese patients examined the safety and effi-
cacy of the SGLT2 inhibitors empagliflozin and dapagliflozin added on
to other oral antihyperglycaemic drugs, including DPP-4 inhibitors.
Although some data (eg, postprandial glucose) were not reported, the
authors mentioned that an SGLT2 inhibitor in combination with a
DPP-4 inhibitor achieved clinically relevant reductions in HbA1c, and
was generally well tolerated.23,24 The safety and efficacy of combina-
tions of SGLT2 inhibitors and DPP-4 inhibitors have also been inves-
tigated in Western patients. For example, a sub-analysis of the
CANVAS trial revealed improvements in HbA1c and body weight
when canagliflozin was added on to a DPP-4 inhibitor or GLP-1
receptor agonist for 18 weeks.25 Some longer-term Western studies
have also been conducted in which dapagliflozin was added on to
sitagliptin (with or without metformin) for 48 weeks,26 or saxagliptin
was added on to dapagliflozin plus metformin for 52 weeks.27 The
results of those studies in Western patients, together with the results
of the present study in Japanese patients, indicate that the combina-
tion of an SGLT2 inhibitor with a DPP-4 inhibitor is likely to be effec-
tive in terms of improving and maintaining glycaemic control for the
long term in patients with T2DM, and ethnic differences are unlikely
to confound the effects of this combination.
The common AEs observed in the present study (ie, those occur-
ring in >5% of patients) were osmotic diuresis, genital infection
(in women), skin disorders and gastrointestinal dysfunction. These
AEs have already been reported for canagliflozin added on to teneli-
gliptin20 and for other DPP-4 inhibitors.22,25 Nevertheless, almost all
of these AEs were mild in severity, and the safety profile for the com-
bination used here did not differ from the known safety profiles of
teneligliptin and canagliflozin; therefore, no new risks requiring addi-
tional precautions were found during long-term treatment as com-
pared with monotherapy.
In the mixed-meal tolerance test conducted in the present study,
the decrease in incremental glucose levels suggests that the combina-
tion decreased postprandial glucose excursions. No increase in post-
prandial glucagon was observed, which was consistent with a
previous double-blind study.20 Although the acute effect of increas-
ing postprandial glucagon was attributed to canagliflozin (300 mg),28
this finding may have resulted from the use of low doses of canagli-
flozin (100 mg) or the suppressive effect of teneligliptin, which was
reported to supress postprandial glucagon levels.29 The present study
also revealed improvements in HOMA2-%B and the proinsulin/C-
peptide ratio, which were maintained until week 52, consistent
with a recent 24-week double-blind study.20 These results suggest
that the combination had sustained effects on β-cell function. The
post-meal improvement in β-cell function, in terms of the C-peptide
AUC0-2h/blood glucose AUC0-2h ratio, was also maintained until week
52. Overall, these findings suggest that the combination decreased
postprandial glucose by enhancing glucose excretion and improving
β-cell function, probably by alleviating glucotoxicity.
Another possible mechanism underlying the effect of the combi-
nation on postprandial glucose is that it might enhance GLP-1 secre-
tion. Oral administration of 100 mg of canagliflozin increased plasma
total GLP-1 after breakfast in Japanese patients with T2DM,30 proba-
bly because of a weak inhibitory effect of canagliflozin against
SGLT1.31 Although we did not measure GLP-1 levels in the present
study, the combination of teneligliptin and canagliflozin may increase
active GLP-1 levels, representing a beneficial effect of this
combination.
In the present study, which is the first to report subgroup ana-
lyses in patients treated with canagliflozin in combination with a
DPP-4 inhibitor, we assessed the safety and efficacy of the combina-
tion in patients subdivided into subgroups on the basis of baseline
HbA1c, BMI and eGFR. We found that the decrease in HbA1c was
greater in subgroups with higher baseline HbA1c and higher baseline
eGFR, but did not differ among the BMI subgroups. Moreover, the
incidence of AEs was similar in each group. These results are consist-
ent with a previous subgroup analysis of canagliflozin.32,33
It has been reported that DPP-4 inhibitors are potentially more
effective in Asian than in non-Asian patients,34 and in Japanese
rather than in non-Japanese patients,35 and Asian people are often
characterized by a lower BMI than other groups. Meanwhile, DPP-4
inhibitors may show decreased efficacy in patients with higher
BMI.34 Considering these concepts, SGLT2 inhibitors may be a useful
addition to the treatment regimen in patients with higher BMI who
respond poorly to a DPP-4 inhibitor. It has also been reported that
body weight management is important for maintaining good long-
term glycaemic control with DPP-4 inhibitors.36,37 In the present
study, the reductions in HbA1c and body weight were maintained for
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52 weeks without attenuation, and 82.24% of patients showed
decreases in both HbA1c and body weight at the end of the treat-
ment period.
Based on these findings, a DPP-4 inhibitor combined with an
SGLT2 inhibitor represents a useful therapeutic option for Japanese
patients with T2DM.
The present study has some limitations that must be acknowl-
edged, including its single-arm, open-label design, and the fact that it
only included Japanese patients. Long-term data on the use of this
combination in Japanese patients are important, however, particularly
when we consider the differences in the pathophysiology, between
Japanese and non-Japanese patients. Importantly, we showed that
this combination was effective and well tolerated over a longer
period than that in a previous 24-week randomized controlled trial.20
Finally, we did not perform statistical hypothesis testing; however,
the changes in variables observed are likely to be clinically relevant
when we consider the 95% CIs did not cross 0.
In conclusion, the results in this cohort of Japanese patients with
T2DM suggest that canagliflozin added on to teneligliptin is tolerable
and effective in individuals whose blood glucose levels cannot be suf-
ficiently controlled by teneligliptin monotherapy. This study showed
that the improvements in glycaemic control were maintained for the
52-week study duration.
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